News | January 18, 2007

Plavix Rival Prasugrel Moves to Phase III Trial

Jan. 19, 2007 — Daiichi Sankyo Co., Ltd. and Eli Lilly and Co. have announced completion of patient enrollment in their pivotal Phase III head-to-head clinical study — TRITON TIMI-38 — to evaluate the safety and efficacy of prasugrel compared with clopidogrel (Plavix) in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI).

Elliott Antman, M.D., director of the Samuel A. Levine Cardiac Unit at Brigham and Women's Medical Center is the study’s lead investigator and senior investigator in the TIMI Study Group.

Specifically, the Phase III study is designed to evaluate the safety and efficacy of prasugrel compared with clopidogrel in reducing ischemic events such as heart attacks, stroke and death in patients with acute coronary syndrome undergoing PCI. The trial is being conducted in conjunction with the TIMI Study Group at Harvard Medical School and Brigham and Women's Hospital in Boston.

Patient enrollment began in November 2004 and has reached a total enrollment of 13,614 patients at more than 700 trial sites in 30 countries. In the U.S. more than 4,063 patients have been enrolled at 313 trial sites, and in Europe, 2,178 patients have been enrolled at 132 sites.

For more information visit and

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init